Myriad Genetics Inc

NASDAQ:MYGNUnited States

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.

Contact Information

Headquarters

322 North 2200 WestSALT LAKE CITY, UT, United States 84116

Phone

801-584-3600

Fax

801-584-3640

Executives

Independent Chairman of the Board

S. Louise Phanstiel

President, Chief Executive Officer, Director

Paul Diaz

Chief Financial Officer

Scott Leffler

President, Chief Clinical Officer - Oncology

George Daneker

Chief Operating Officer

Sam Raha